Product: Talimogene Laherparepvec Clinical Study Report: Date: 31 October 2018 Page 1
|
|
- Terence Simmons
- 5 years ago
- Views:
Transcription
1 Date: 31 October 2018 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Imlygic Name of Active Ingredient: Talimogene laherparepvec Title of Study: A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects with Unresected, Stage IIIB to IVM1c Melanoma Investigators and Study Centers: This study was conducted at 11 centers in the United States of America and Canada (Section ). Publications: Andtbacka RH, Mehnert J, Nemunaitis J, et al. Phase 2 Trial Evaluating Biodistribution and Shedding of Talimogene Laherparepvec in Patients With Unresectable Stage IIIB-IV Melanoma. [abstract] Mol Ther May;25(No 5S1). Abstract 16. Andtbacka RH, Mehnert J, Nemunaitis J, et al. Biodistribution and Shedding of Talimogene Laherparepvec (T-VEC) in Patients (Pts) With Unresectable Stage IIIB/IV Melanoma. [SMR Congress 2017 abstract] Pigment Cell Melanoma Res. 2018;31: Study Period: 07 April 2014 (first subject enrolled) 19 April 2018 (last subject completed follow-up) The analyses provided in this report are based on a database lock date of 22 June Development Phase: 2 Previous Reports for This Study: Primary Analysis, dated 20 October 2016; Interim report, dated 28 May 2015 Objectives and Endpoints: Objectives Primary Endpoints to estimate the proportion of subjects with detectable talimogene laherparepvec DNA in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles prevalence of detectable talimogene laherparepvec DNA: proportions of subjects with detectable talimogene laherparepvec DNA in the blood and urine any time after the administration of talimogene laherparepvec within the first 3 cycles
2 Date: 31 October 2018 Page 2 Objectives Secondary Endpoints to estimate the incidence of clearance of talimogene laherparepvec DNA from blood and urine overall and by baseline herpes simplex virus type 1 (HSV-1) serostatus (seronegative versus seropositive) during each of the first 3 cycles incidence of clearance of talimogene laherparepvec DNA to estimate the rate of detection and subject laherparepvec DNA and virus from exterior of occlusive dressing and surface of injected lesion viral detection on the exterior of the occlusive dressing during treatment to estimate the rate of detection and subject laherparepvec DNA and virus in oral mucosa swabs during treatment and after end of treatment viral detection from the surface of injected lesions during treatment viral detection in oral mucosa swabs during treatment viral detection in oral mucosa swabs after the end of treatment to estimate the rate of detection and subject laherparepvec DNA and virus in swabs from the anogenital area during treatment and after the end of treatment viral detection in swabs from the anogenital area during treatment viral detection in swabs from the anogenital area after the end of treatment to estimate the incidence of detection of talimogene laherparepvec DNA in lesions suspected to be herpetic in origin laherparepvec DNA detection in lesions suspected to be herpetic in origin
3 Date: 31 October 2018 Page 3 Objectives Secondary (continued) Endpoints to describe the efficacy of talimogene laherparepvec as assessed by objective response rate, best overall response rate, duration of response, and durable response rate achieved in subjects with unresected, stage IIIB to IVM1c melanoma objective response rate (ORR) (per modified World Health Organization [WHO] criteria) best overall response rate (per modified WHO criteria) duration of response time to response (TTR) durable response rate (DRR) (defined as complete response [CR] or partial response [PR] of 6 months or longer) overall survival to describe the safety profile of talimogene laherparepvec in subjects with unresected, stage IIIB to IVM1c melanoma Methodology: subject incidence of treatment-emergent and treatment-related adverse events (including all adverse events, grade 3 adverse events, serious adverse events, fatal adverse events, events of interest, adverse events requiring the discontinuation of investigational product, and clinically significant laboratory changes) This phase 2, multicenter, single-arm study was designed to investigate the biodistribution and shedding of talimogene laherparepvec in subjects with unresected, stage IIIB to IV M1c melanoma. Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10 6 plaque-forming units (PFU) per ml followed by a dose of 10 8 PFU/mL 21 days after the initial dose and every 14 (± 3) days thereafter. Each injection marked the beginning of a new treatment cycle; the first cycle was 21 days in length, and subsequent cycles were 14 (± 3) days in length. Subjects were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first. Subjects were followed for safety for up to 60 (+ 7) days at time points designated in the protocol per the schedule of assessments. Thereafter, subjects were to be followed under an ongoing separate registry protocol evaluating the long-term survival of subjects treated with talimogene laherparepvec in clinical studies (Study ). The registry protocol also monitors for late and long-term adverse events thought to be potentially related to talimogene laherparepvec and anti-cancer therapy for melanoma.
4 Date: 31 October 2018 Page 4 Samples (blood, urine, swabs from oral mucosa, swabs from the anogenital area [added as of Protocol Amendment 1 (Section of this report)], swabs from the exterior of the occlusive dressing and the surface of injected lesions, and swabs of lesions suspected to be of herpetic origin) were collected to evaluate the biodistribution and shedding of talimogene laherparepvec during the treatment period and safety follow-up at time points designated in the protocol per the schedule of assessments. Number of Subjects Planned: Approximately 50 to 60 Diagnosis and Main Criteria for Eligibility: Eligible subjects were men and women 18 years of age with a histologically confirmed diagnosis of unresected stage IIIB, IIIC, IV M1a, IV M1b, or IV M1c melanoma, regardless of prior line of therapy. Subjects were required to be candidates for intralesional therapy administration into cutaneous, subcutaneous, or nodal disease and were also required to have measurable disease, serum lactate dehydrogenase 1.5 x upper limit of normal, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate hematologic, hepatic, and renal organ function. Subjects must not have had > 3 visceral metastases (not including lung metastases or any nodal metastases associated with visceral organs) or any bone metastases, primary ocular or mucosal melanoma, history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or symptomatic autoimmune disease, or evidence of immunosuppression for any reason. Investigational Products, Dose and Mode of Administration, Manufacturing Batch Number: Talimogene laherparepvec was supplied as a sterile frozen liquid in single-use vials containing a minimum of 1.0 ml talimogene laherparepvec at concentrations of either 10 6 PFU/mL or 10 8 PFU/mL. Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions with or without image ultrasound guidance. The initial dose of talimogene laherparepvec was up to 4.0 ml of 10 6 PFU/mL. Subsequent doses of talimogene laherparepvec were up to 4.0 ml of 10 8 PFU/mL. The second dose was to be administered 21 (+ 5) days after the initial dose, and subsequent doses were to be given every 14 (± 3) days. Manufacturing batch numbers are provided in Section Duration of Treatment: The duration of treatment varied for each subject (see Methodology). Statistical Methods: This study was completed, and this report describes the final analysis of the study (ie, conducted after all enrolled subjects had a chance to complete their 60-day safety follow-up visit) as prespecified in the statistical analysis plan. The primary endpoint, the proportion of subjects with detectable talimogene laherparepvec DNA in blood and urine after investigational product administration during the first 3 cycles, was analyzed using the blood/urine evaluable analysis set. The point-wise exact 95% confidence intervals (CI) for the binomial proportion were provided using F-distributions. The number and proportion of subjects with clearance of talimogene laherparepvec DNA per quantitative polymerase chain reaction (qpcr) analysis at cycles 1, 2, and 3 after
5 Date: 31 October 2018 Page 5 positive qpcr testing in each cycle were summarized. Exact 95% CIs were calculated using the F-distribution. Summary statistics were calculated for the incidence (overall and by time point) of talimogene laherparepvec DNA detection (and viral detection by the 50% tissue culture infective dose [TCID 50] assay) in swabs collected from oral mucosa, the anogenital area, exterior of the occlusive dressing, and surface of injected lesions. Subject incidence was defined as the proportion of subjects having detectable talimogene laherparepvec DNA or detectable talimogene laherparepvec virus among subjects who provided samples. Rate of detection was defined as the proportion of samples exhibiting detection of talimogene laherparepvec DNA or detection of talimogene laherparepvec virus. The laherparepvec DNA detection in lesions suspected to be herpetic in origin was also summarized. Exact 95% CIs were calculated using the F-distribution. Subject incidence rates of treatment-emergent adverse events after the initiation of therapy through the 30-day safety follow-up visit were summarized. In addition, subject incidence rates of serious adverse events from the 30-day safety follow-up visit to the 60-day safety follow-up visit were summarized. Clinically significant laboratory changes and clinically significant changes in vital signs were summarized using descriptive statistics. Potential or known unintended exposure to talimogene laherparepvec, related suspected signs or symptoms, and detection of talimogene laherparepvec DNA in a subject s household member, caregiver, or healthcare provider were summarized. Summary of Results: Subject Disposition: A total of 61 subjects were enrolled at 11 centers in the United States and Canada. Sixty subjects received at least 1 dose of investigational product and were included in the safety analysis set. Baseline Demographics: Sex: men (55.0%); women (45.0%) Age: mean (standard deviation [SD]; range): 63.3 (16.7, 19 to 93) years Race: white (100.0%)Ethnicity: not Hispanic or Latino (100.0%) Disease Stage at Baseline: IIIB (16.7%); IIIC (53.3%); IVM1a (18.3%); IVM1b (5.0%); IVM1c (6.7%) ECOG Performance Status at Baseline: 0 (75.0%); 1 (25.0%) BRAF Mutation: mutation (33.3%); wild type (63.3%); other 1 (1.7%); missing 1 (1.7%) Efficacy Results: The ORR was 35.0%, including 9 subjects (15.0%) with a CR and 12 subjects (20.0%) with a PR. Median actual follow-up time was 28.9 weeks (range: 4 to 151 weeks). The median TTR (95% CI) among all subjects in the safety analysis set was 8.7 (5.3, not estimable) months. Among responders (N = 21), the median TTR was 3.1 (2.6, 5.3) months. All 21 responders were in response as of their last assessment during the study, with a median duration of response that was not reached (95% CI: not estimable not estimable), including 3 subjects (5.0%) who met the criteria for a durable response.
6 Date: 31 October 2018 Page 6 Overall survival was 100% during the study reporting period; however, there was no long-term follow-up in this study. Talimogene Laherparepvec Biodistribution and Shedding Results: As noted in the table below, the incidence of subjects and samples with detectable talimogene laherparepvec DNA (as assayed by qpcr) varied by the type of sample that was taken. Talimogene laherparepvec DNA was detected in blood in 98.3% of subjects and in urine in 31.7% of subjects. Subjects With Detectable Talimogene Laherparepvec DNA Any Time During the Study a Baseline HSV-1 Seronegativ e (N=17) b n/m (%) c Blood 17/17 (100.0) Urine 5/17 (29.4) Injected lesions Exterior of occlusive dressing Oral mucosa Anogenita l Area 17/17 (100.0) 13/17 (76.5) 4/17 (23.5) 0/7 (0.0) Baseline HSV-1 Seropositiv e (N=40) b n/m (%) c 39/40 (97.5) 14/40 (35.0) 40/40 (100.0) 33/40 (82.5) 3/40 (7.5) 5/17 (29.4) Overall (N=60) b n/m (%) c 59/60 (98.3) 19/60 (31.7) 60/60 (100.0) 48/60 (80.0) 8/60 (13.3) 5/26 (19.2) Samples With Detectable Talimogene Laherparepvec DNA Any Time During the Study a Baseline HSV-1 Seronegative n/m (%) d 136/311 (43.7) 9/308 (2.9) 168/399 (42.1) 51/289 (17.6) 8/302 (2.6) 0/123 (0.0) Baseline HSV-1 Seropositive n/m (%) d 234/728 (32.1) 22/725 (3.0) 519/1045 (49.7) 145/741 (19.6) 3/599 (0.5) 7/244 (2.9) Overall n/m (%) d 383/1094 (35.0) 31/1088 (2.8) 741/1520 (48.8) 212/108 5 (19.5) 12/964 (1.2) HSV = herpes simplex virus; qpcr = quantitative polymerase chain reaction a For oral mucosa and the anogenital area, values represent any time during treatment. b N = number of subjects in the analysis set. c n = number of subjects with positive qpcr testing result; m = number of subjects with samples collected. d n = number of samples with positive qpcr testing result; m = number of samples collected. Source: Table , Table , Table , Table , Table , Table , Table , Table , Table , Table , Table , Table /448 (1.6) The proportion of samples with detectable talimogene laherparepvec DNA in blood and urine was highest during the second cycle of treatment and was 0 at the safety follow-up visit (30 days after the end of treatment). No samples from the oral mucosa or anogenital region had detectable talimogene laherparepvec DNA after the end of treatment (at all timepoints: safety follow-up day 30, between day 30 and 60, and day 60). While talimogene laherparepvec DNA was detected in the injected lesions of all subjects at some point during the study, no samples from injected lesions were positive for talimogene laherparepvec DNA 60 (+ 7) days after the end of treatment. Overall, during the study, 3 of 19 subjects had samples from lesions of suspected herpetic origin that had detectable talimogene laherparepvec DNA. These 4 lesions
7 Date: 31 October 2018 Page 7 (located on the breast, right arm/axilla, and oral cavity) had not been injected during the study. Samples that were positive for talimogene laherparepvec DNA from the surface of injected lesions, the exterior of occlusive dressings, the oral mucosa, and lesions of suspected herpetic origin were tested for viral infectivity using the TCID 50 method. No samples from the exterior of occlusive dressings, oral mucosa, or lesions of suspected herpetic origin had detectable talimogene laherparepvec viral activity by TCID 50 assay. For injected lesions, 8 of 740 samples (1.1%) from 7 of 60 subjects (11.7%) were positive for viral activity by a TCID 50 assay. Seven of the positive samples were from cycle 1 (4 positive samples from cycle 1 day 3 and 3 positive samples from cycle 1 day 8), and 1 positive sample was from cycle 2 (day 3); no samples tested positive for viral activity by TCID 50 assay after cycle 2. Among subjects who had detectable talimogene laherparepvec DNA in the blood or urine during cycle 1, most were clear before the next dose (38 of 41 subjects [92.7%] blood; 3 of 3 [100.0%] urine). Similarly, most subjects with detectable talimogene laherparepvec DNA in the blood or urine during cycle 2 were clear before the third dose (49 of 57 subjects [86.0%] blood; 13 of 14 [92.9%] urine). Three subjects had detectable DNA in the blood during cycle 3, and 1 of these (33.3%) cleared talimogene laherparepvec DNA before the next dose. Two subjects had detectable DNA in the urine during cycle 3, and both subjects (100.0%) cleared talimogene laherparepvec DNA before the fourth dose. No subjects had detectable talimogene laherparepvec DNA in the blood or urine at the 30-day safety follow-up visit. During cycles 1 and 2, the subject incidence for talimogene laherparepvec DNA blood clearance was higher among subjects who were HSV-1 seropositive at baseline versus those who were seronegative at baseline (100% vs 78.6%, respectively, in cycle 1 and 94.7% vs 64.7% in cycle 2). Few subjects had detectable talimogene laherparepvec in urine samples; as a result, comparisons of clearance between subjects who were seropositive versus seronegative at baseline are not meaningful. Safety Results: A total of 60 subjects were treated for a mean (standard deviation [SD]) of 14.5 (11.5) visits (median [minimum, maximum]: 12 [2, 71] visits) over (23.71) weeks (median [minimum, maximum]: 23.1 [3.1, 141.1] weeks). The mean (SD) volume for the first injection was 2.62 (1.30) ml of 10 6 PFU/mL talimogene laherparepvec. For all other doses, the mean (SD) volume of injection was 2.50 (1.23) ml of 10 8 PFU/mL. Overall, 60 subjects (100%) had 1 treatment-emergent adverse event during the study, and most subjects (57 subjects [95.0%]) had 1 adverse event that was related to investigational product. The most common adverse events ( 25%) were chills (65.0%), fatigue (56.7%), headache (45.0%), nausea (45.0%), pyrexia (40.0%), injection site pain, pain, and vomiting (each in 25.0%). Of the adverse events that were grade 3 or higher in severity, the events of upper abdominal pain, delirium, and fatigue (2 subjects [3.3%] each) were reported in > 1 subject. One subject had an event of lymphopenia that was grade 4 in severity. None of the subjects had fatal adverse events. Thirteen subjects (21.7%) had 1 serious adverse events. Serious adverse events reported in > 1 subject were delirium and pyrexia (2 subjects, 3.3% each).
8 Date: 31 October 2018 Page 8 Events of interest were reported for 59 subjects (98.3%). The most common events of interest ( 20% identified by the narrow search strategy) were in the categories of flu-like symptoms (57 subjects [95.0%]), impaired wound healing (28 subjects [46.7%]), injection site reactions (28 subjects [46.7%]), rash (22 subjects [36.7%]), and hypersensitivity (19 subjects [31.7%]). Most subjects had events that were grade 1 (24 subjects [40.0%]) or grade 2 (28 subjects [46.7%]) in severity. Events of interest reported as serious included pyrexia, delirium (2 subjects each), body temperature increased, influenza-like illness, posterior reversible encephalopathy syndrome, cellulitis, congestive cardiac failure, and deep vein thrombosis (1 subject each). Conclusions: Talimogene laherparepvec biodistribution and shedding data from this final analysis were comparable with those reported previously for the primary analysis. Talimogene laherparepvec DNA was detected with the lowest frequency in samples from the oral mucosa (12 of 964 samples [1.2%] and 8 of 60 subjects [13.3%]), from the anogenital area (7 of 448 samples [1.6%] and 5 of 26 subjects [19.2%]), and in urine (31 of 1088 samples [2.8%] and 19 of 60subjects [31.7%]). In contrast, and consistent with the method of administration, talimogene laherparepvec DNA was detected with the greatest frequency in swabs of injected lesions (741 of 1520 samples [48.8%] and 60 of 60 subjects [100.0%]) and in the blood (383 of 1094 samples [35.0%] and 59 of 60 subjects [98.3%]). Most of the samples with detectable talimogene laherparepvec DNA were obtained during cycle 2 when talimogene laherparepvec was administered in concentration of 10 8 PFU/mL for the first time. Overall, 3 of 19 subjects had detectable talimogene laherparepvec DNA by qpcr testing from swabs of lesions of suspected herpetic origin; these lesions had not been injected during the study. The clearance rate of talimogene laherparepvec DNA from the blood was 92.7% before cycle 2 and 86.0% before cycle 3. The subjects who were HSV-1 seropositive at baseline had a numerically higher clearance of talimogene laherparepvec DNA from the blood during cycles 1 and 2 (100% and 94.7%, respectively), compared with subjects who were seronegative at baseline (78.6% and 64.7%, respectively). Among the swab samples collected, the incidence of viral infectivity by TCID 50 assay was low (8 of 740 samples [1.1%] and 7 of 60 subjects [11.7%]) with all positive samples obtained from injected lesions. Seven of these samples were from cycle 1, and 1 positive sample was from cycle 2; no swabs had detectable talimogene laherparepvec viral activity by TCID 50 testing after cycle 2. The ORR was 35.0%, including 9 subjects (15.0%) with a CR and 12 subjects (20.0%) with a PR. All 21 responders were continuing to respond as of their last assessment during the study, including 3 subjects (5.0%) who met the criteria for a durable response.
9 Date: 31 October 2018 Page 9 Safety data from this final analysis were comparable with those reported previously for the primary analysis including the type, frequency, and severity of adverse events, serious adverse events, and adverse events leading to discontinuation of investigational product. The most common adverse events ( 25%) were chills (65.0%), fatigue (56.7%), headache (45.0%), nausea (45.0%), pyrexia (40.0%), injection site pain, pain, and vomiting (each in 25.0%). Thirteen subjects had serious adverse events and no subjects died during the study. Serious adverse events of delirium and pyrexia were reported in 2 subjects (3.3%) each; all other serious adverse events occurred in a single subject each. The serious events were consistent with the viral nature of talimogene laherparepvec, subjects existing medical history, and/or prior therapies received.
Summary of the risk management plan (RMP) for Imlygic (talimogene laherparepvec)
EMA/713818/2015 Summary of the risk management plan (RMP) for Imlygic ( laherparepvec) This is a summary of the risk management plan (RMP) for Imlygic, which details the measures to be taken in order to
More informationNAME OF THE MEDICINE IMLYGIC is the Amgen Inc. trademark for talimogene laherparepvec (rmv).
IMLYGIC (talimogene laherparepvec) Product Information Page 1 of 19 NAME OF THE MEDICINE IMLYGIC is the Amgen Inc. trademark for talimogene laherparepvec (rmv). DESCRIPTION Talimogene laherparepvec is
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationTalimogene Laherparepvec (T-VEC) at the SCCA: an update
Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationViewpoint from a health care professional
Viewpoint from a health care professional Christoph Hoeller Skin Cancer Center at the Department of Dermatology Medical University of Vienna Austria Certified Skin Tumor Center The fifth annual regulatory
More informationREQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC
REQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC The Cancer Therapy Evaluation Program (CTEP) is accepting Project Team Member Applications (PTMAs)
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationInnovative Combination Strategies: Oncolytic and Systemic Therapy
Innovative Combination Strategies: Oncolytic and Systemic Therapy Sanjiv S. Agarwala, MD Professor of Medicine, Temple University Chief, Oncology & Hematology St. Luke s Cancer Center Bethlehem, PA, USA
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationTitle A Phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
Sponsor Novartis Generic Drug Name Panobinostat Therapeutic Area of Trial Refractory cutaneous T-Cell lymphoma Approved Indication Investigational drug Protocol Number CLBH589B2201 Title A Phase II study
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationSurgical Oncology Perspective of Melanoma
Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives
More informationBACKGROUND INFORMATION FOR JOINT MEETING OF THE CELLULAR, TISSUE, AND GENE THERAPY, AND ONCOLOGIC DRUGS ADVISORY COMMITTEES 29 APRIL 2015
Talimogene laherparepvec Page 1 BACKGROUND INFORMATION FOR JOINT MEETING OF THE CELLULAR, TISSUE, AND GENE THERAPY, AND ONCOLOGIC DRUGS ADVISORY COMMITTEES 29 APRIL 2015 BIOLOGICAL LICENSE APPLICATION
More informationTHE IMLYGIC STORY: A WINDING PATH TO INNOVATION
THE IMLYGIC STORY: A WINDING PATH TO INNOVATION EBE Workshop EU CASSS 22 May 2017 MICHAEL ABERNATHY EXECUTIVE DIRECTOR, RA CMC WHY DO WE INNOVATE? Today, one of these children has Stage IV pancreatic cancer
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationDisclosures Information Brendan D. Curti, MD
The MITCI (Phase 1b) study: A novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationStudy Period: 27 March 2008 (first subject enrolled) to 05 May 2010 (data cutoff date for primary analysis)
Date: 20 July 2011 Page 2 of 3375 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C US Name of Finished Product: Not applicable Name of ctive Ingredient: Ganitumab (MG 479) Title of Study: n International,
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015 ClinicalTrials.gov ID: NCT01378962 Study Identification Unique Protocol ID: ML25514 Brief Title: A Study
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More information2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)
2.0 Synopsis Abbott Laboratories Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTwo roads for oncolytic immunotherapy development
Kaufman and Bommareddy Journal for ImmunoTherapy of Cancer (2019) 7:26 https://doi.org/10.1186/s40425-019-0515-2 COMMENTARY Two roads for oncolytic immunotherapy development Howard L. Kaufman 1,2* and
More informationProduct: Blinatumomab Clinical Study Report: MT Date: 11 July 2014 Page 1
Date: 11 July 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich) GmbH Name of Finished Name of Active Ingredient: Blinatumomab, a murine recombinant single-chain antibody derivative that
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationSingle Technology assessment
Single Technology assessment Talimogene laherparepvec (Imlygic/T-Vec) for the treatment of malign melanoma 01-03-2017 Norwegian Medicines Agency Brev stiles til Statens legemiddelverk. Vennligst oppgi
More informationS^t _j4 A-N.1^.^ A _ WE 2
S^t _j4 A-N.1^.^ A _ WE 2 Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to RANKL Title of Study: A Randomized Study
More informationStudy No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationINTRODUCTION. KEY WORDS: cutaneous head and neck melanoma, talimogene laherparepvec, oncolytic virus, cancer immunotherapy
ORIGINAL ARTICLE Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationPatterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial Robert H.I. Andtbacka, University of Utah Merrick Ross, MD Anderson
More informationCombiRT in Metastatic Melanoma Trial
CombiRT in Metastatic Melanoma Trial An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy
More informationReferring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-333, ribavirin Name of Active Ingredient: ABT-450: (2R,6S,12Z,13aS,14aR,16aS)-N- (cyclopropylsulfonyl)-6-{[(5- methylpyrazin-2-yl)carbonyl]amino}-
More informationPrincipal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom
SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationIndividual Study Table Referring to Part of the Dossier. Page:
2. SYNOPSIS Title of Study: A comparative study of the pharmacokinetic/pharmacodynamic and safety profiles of extended release, regular release and placebo during a 12 hour observation in post-extraction
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationFull Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationReferring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationOverview of Intralesional Therapy for Melanoma
Overview of Intralesional Therapy for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine, Temple University Chief, Oncology & Hematology St. Luke s Cancer Center Bethlehem, PA, USA Overview Introduction
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationProduct: Blinatumomab (AMG 103) Clinical Study Report: MT Date: 19 April 2013 Page 2 of 9510
Date: 19 April 2013 Page 2 of 9510 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich), formerly Micromet AG/Micromet GmbH, Staffelseestrasse 2, 81477 Munich, Germany Name of Finished Product: Blinatumomab
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More information